The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•3 April 2026•

1 min read

Abbott Stock Trades 26% Below Peak as Analysts See 28% Upside Potential

Key Facts

1Abbott Laboratories (ABT) stock is trading near its 52-week low, 26% off its peak.

2The company recently acquired Exact Sciences for $23 billion to enter the cancer screening market.

3Analysts have a mean price target of $132.28, implying a 28.6% upside potential.

Create Free Account

Abbott Laboratories (ABT) shares are currently trading near their 52-week lows, representing a 26% decline from their recent peak. Despite the price pressure, analysts remain bullish with a mean price target of $132.28, implying a potential upside of 28.6%. The company recently completed a strategic $23 billion acquisition of Exact Sciences, marking a significant entry into the high-growth cancer screening market. Furthermore, the FreeStyle Libre continuous glucose monitor business continues to demonstrate robust growth, bolstering the firm's core medical device segment. This expansion, combined with strong free cash flow, suggests that the current market valuation may undervalue Abbott's long-term prospects. Investors are closely watching the stock's performance as it prepares for its upcoming Q1 2026 earnings report.